PCM
DSGN icon

Prelude Capital Management’s Design Therapeutics DSGN Stock Holding History

Prelude Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,985
Closed -$86K – 1288
2024
Q3 		$86K Sell
15,985
-16,971
-51% -$79.8K 0.01% 1168
2024
Q2 		$110K Sell
32,956
-15,644
-32% -$61K 0.01% 1089
2024
Q1 		$196K Hold
48,600
– – 0.01% 1120
2023
Q4 		$129K Buy
48,600
+15,200
+46% +$34.8K 0.01% 1005
2023
Q3 		$78.8K Buy
+33,400
New +$156K 0.01% 1013

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's DSGN Position: Q4 2024 in Review

Prelude Capital Management sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 15,985 shares — an estimated $86K sold.

Prelude Capital Management first reported a position in DSGN in Q3 2023 and held it in 5 quarters. The position peaked at $196K in Q1 2024. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

  • Prelude Capital Management reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 15,985 Design Therapeutics shares in Q4 2024, an estimated $86K.
  • Prelude Capital Management first reported a position in Design Therapeutics in Q3 2023 and held it in 5 quarters.
  • Prelude Capital Management's Design Therapeutics position peaked at $196K in Q1 2024.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.